Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$147.47
+3.9%		$144.91
$82.01
▼
$156.92
$350.29B0.219.93 million shs9.80 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$226.30
+4.6%		$149.83
$22.28
▼
$227.46
$90.35B1.0918.00 million shs16.56 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+3.87%+3.37%+1.83%+15.51%+73.86%
Moderna, Inc. stock logo
MRNA
Moderna
+4.65%+15.18%+54.27%+258.35%+762.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$147.47
+3.9%		$144.91
$82.01
▼
$156.92
$350.29B0.219.93 million shs9.80 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$226.30
+4.6%		$149.83
$22.28
▼
$227.46
$90.35B1.0918.00 million shs16.56 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+3.87%+3.37%+1.83%+15.51%+73.86%
Moderna, Inc. stock logo
MRNA
Moderna
+4.65%+15.18%+54.27%+258.35%+762.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.63
Moderate Buy$151.923.02% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.12
Hold$101.45-55.17% Downside

Current Analyst Ratings Breakdown

Latest MRNA and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Moderna, Inc. stock logo
MRNA
Moderna
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$120.00 ➝ $137.00
10/12/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$125.00 ➝ $145.00
10/12/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetSector Perform$150.00 ➝ $145.00
10/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$170.00 ➝ $200.00
10/8/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$120.00 ➝ $145.00
10/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price Target$50.00 ➝ $80.00
10/7/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$179.00 ➝ $177.00
10/7/2026
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$89.00 ➝ $95.00
10/5/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$150.00 ➝ $165.00
9/30/2026
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeNeutral ➝ Sell$60.00 ➝ $80.00
9/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetSector Outperform$155.00 ➝ $180.00
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$66.57B5.47$11.86 per share12.43$21.22 per share6.95
Moderna, Inc. stock logo
MRNA
Moderna
$2.21B40.88N/AN/A$22.14 per share10.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$1.25117.9715.916.564.77%16.73%6.13%10/29/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/6/2026 (Estimated)

Latest MRNA and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026Q3 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$1.10N/AN/AN/A$892.40 millionN/A
10/29/2026Q3 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.09N/AN/AN/A$17.27 billionN/A
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.31%+5.75%272.00%14 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest MRNA and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.36%9/15/20269/15/202610/7/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.22
1.32
1.10
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable

Recent News About These Companies

Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-moderna-nasdaq-mrna-stock-price-expected-to-rise-the-goldman-sachs-group-analyst-says-2026-10-15/
Strategy Asset Managers LLC Purchases 13,021 Shares of Moderna, Inc. $MRNA
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-strategy-asset-managers-llc-purchases-13021-shares-of-moderna-inc-mrna-2026-10-15/
Promising Biotech Stocks To Follow Today - October 13th
October 15 at 1:04 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31120349
Moderna (NASDAQ:MRNA) Stock Price Up 4.6% - Time to Buy?
October 14 at 5:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-moderna-nasdaq-mrna-stock-price-up-46-time-to-buy-2026-10-14/
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
October 14 at 1:24 PM  |  cnbc.comhttps://www.cnbc.com/2026/10/14/merck-moderna-cancer-vaccine-manufacturing-time.html
Top Healthcare Stocks To Research - October 14th
October 14 at 1:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-top-healthcare-stocks-to-research-october-14th-2026-10-14/
Top Biotech Stocks To Research - October 14th
October 14 at 12:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-top-biotech-stocks-to-research-october-14th-2026-10-14/
Moderna, Inc. $MRNA Shares Sold by Contravisory Investment Management Inc.
October 13 at 7:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-moderna-inc-mrna-shares-sold-by-contravisory-investment-management-inc-2026-10-13/
Moderna (NASDAQ:MRNA) Shares Up 1.2% - Here's Why
October 13 at 5:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-moderna-nasdaq-mrna-shares-up-12-heres-why-2026-10-13/
Sivik Global Healthcare LLC Makes New Investment in Moderna, Inc. $MRNA
October 13 at 1:27 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sivik-global-healthcare-llc-makes-new-investment-in-moderna-inc-mrna-2026-10-13/
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
October 13 at 1:15 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/mrna-stock-gains-over-4b-150100044.html
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
October 13 at 1:05 PM  |  zacks.comhttps://www.zacks.com/stock/news/3006316/mrna-stock-gains-over-4b-in-a-week-time-to-buy-hold-or-sell?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-3006316
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
October 13 at 11:21 AM  |  businessinsider.comhttps://www.businessinsider.com/ftc-martin-shkreli-lifetime-pharma-ban-contempt-2026-10
Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
October 13 at 8:15 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-report-third-quarter-2026-110000489.html
Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
October 13 at 7:00 AM  |  accessnewswire.comA
Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
October 13 at 4:44 AM  |  fool.comhttps://www.fool.com/investing/2026/10/13/moderna-is-now-worth-more-than-3x-as-much-as-biont/
Health Canada reviewing new mRNA flu vaccine that could prevent more hospitalisations
October 12 at 7:32 PM  |  thenews.com.pkT
Where Could Moderna's Next Growth Come From?
October 12 at 7:32 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/where-could-modernas-next-growth-210142193.html
Here's Why Moderna (MRNA) Fell More Than Broader Market
October 12 at 6:51 PM  |  zacks.comhttps://www.zacks.com/stock/news/3005510/here-s-why-moderna-mrna-fell-more-than-broader-market?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v1-3005510
How Moderna's new mRNA vaccine could change future flu seasons
October 12 at 2:31 PM  |  msn.comhttps://www.msn.com/en-us/health/diseases-and-conditions/how-moderna-s-new-mrna-vaccine-could-change-future-flu-seasons/vi-AA2e4yi5
Moderna’s (MRNA) Cancer Vaccine Breakthrough Drives Sharp Stock Rally
October 12 at 2:31 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-mrna-cancer-vaccine-breakthrough-142707782.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$147.47 +5.49 (+3.86%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$148.85 +1.38 (+0.94%)
As of 08:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna stock logo

Moderna NASDAQ:MRNA

$226.30 +10.05 (+4.65%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$221.98 -4.33 (-1.91%)
As of 08:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas